Approximately, 20-40% patients with diabetes achieve the glycemic target (A1C< 7%), globally. A retrospective analysis of glycemic trends based on A1C across three diabetes speciality centers [metro city (A), second tier city (B), district headquarter (C)] including 11,162 patients [A (n=3601), B (n=815), C (n=6746)] either newly diagnosed or following up at over past two years, was undertaken. Being treated as per standard guidelines with at least one HbA1c level reported within this period and classified as well-controlled (A1C <7%) or uncontrolled (A1C <7%) based on glycemic factorization. Table 1 shows the ANOVA results[1264 patients (11.32%) achieving an A1C <6%, and 2709 patients (24.27%) between 6-6.9% across centers]; representing well-controlled patients and the uncontrolled patient population (A1C>7%). The latter group with 22.52% (n=2514) and 23.49% (n=2622) patients with A1C between 7-7.9% and 8-9.9% respectively, represented a group that should be aggressively treated to mitigate the “missed opportunities” in achieving glycemic control and increase the overall percentage of patients achieving target goals. Furthermore, sub-group analyses across individual centers (A, B, C) revealed that differences in factorized HbA1c levels were statistically highly significant (p=0.002) necessitating a high-quality, uniform standard of care, irrespective of the setting to help burden of this disease.

Table 1 - Glycemic Factorisation Across Three Different Diabetes Care Centers Over 24 Months.

HbA1c Factorisation Metro City (A) Second Tier City (B) District Headquarter (C) Total Percentage (%) 
< 6 261 52 951 1264 11.32 
6-6.9 999 187 1523 2709 24.27 
7-7.9 1037 191 1286 2514 22.52 
8-9.9 911 224 1487 2622 23.49 
10-10.9 183 72 482 737 6.6 
11-11.9 116 30 361 507 4.54 
>12 94 59 656 809 7.25 
Total 3601 815 6746 11162  
HbA1c Factorisation Metro City (A) Second Tier City (B) District Headquarter (C) Total Percentage (%) 
< 6 261 52 951 1264 11.32 
6-6.9 999 187 1523 2709 24.27 
7-7.9 1037 191 1286 2514 22.52 
8-9.9 911 224 1487 2622 23.49 
10-10.9 183 72 482 737 6.6 
11-11.9 116 30 361 507 4.54 
>12 94 59 656 809 7.25 
Total 3601 815 6746 11162  

Disclosure

P.M. Chawla: Speaker's Bureau; Self; Sanofi. Speaker's Bureau; Spouse/Partner; Eli Lilly and Company, IPCA LABORATORIES, Novo Nordisk A/S, MSD PHARMACEUTICALS PVT. LTD., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. C. Ashtekar: Speaker's Bureau; Self; Novo Nordisk A/S, USV Private Limited, MSD Pharmaceuticals Pvt. Ltd., Abbott, LUPIN, Eris Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation. R.M. Dhope: Speaker's Bureau; Self; USV Private Limited, SUNPHARMA, LUPIN, Novartis Pharmaceuticals Corporation, AstraZeneca, SERDIA PHARMACEUTICALS, GLENMARK. A.F. Shaikh: None. M.C. Kothari: None. M.S. Chawla: Speaker's Bureau; Self; IPCA Laboratories, Eli Lilly and Company, Novo Nordisk A/S, MSD Pharmaceutical Pvt. Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. Speaker's Bureau; Spouse/Partner; Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.